Latest News-ASIERIS Mediaroom_Page

NMPA accepted the registration applications for Uro-G and Uro-3500

SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma compan...

2023-02-21 17:46 1917

Asieris Appoints Dr. Linda Wu as Chief Development Officer

SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma comp...

2023-01-18 07:00 2204

Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma compan...

2022-12-12 20:59 1652

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma compan...

2022-12-12 17:47 1617

The First IBCC Unveiled in Hainan

SHANGHAI, Dec. 5, 2022 /PRNewswire/ -- The first Integrated Bladder Cancer Center (IBCC) inHainan P...

2022-12-05 15:55 1378

Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma compan...

2022-11-10 19:02 2015

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

SHANGHAI, Nov. 6, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharmaceutical company ...

2022-11-07 10:04 1497

Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma co...

2022-09-15 17:07 1393

Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharma company specia...

2022-08-25 00:46 2493

Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy

Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board

An expert in genitourinary oncology, Dr. Konety brings deep academic insight, broad clinical expert...

2022-08-10 16:09 1684

Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board

Asieris to present a study protocol of APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy（NAC）for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting

SHANGHAI, May 27, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative bio...

2022-05-27 22:16 2967

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative p...

2022-04-14 22:49 2254

Hexvix® Has Obtained CDE Approval for the Inclusion In the Clinical Real-world Evidence Pilot Study

SHANGHAI, March 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative b...

2022-03-14 14:25 1540

Asieris Announces the World's First Patient Dose Administered in Combination of Asieris'APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, Jan. 3, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a global innovative pharm...

2022-01-04 08:06 1657

The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the ...

2021-10-13 15:47 1266

Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research

SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced the appointment of Dr.Al...

2021-09-22 14:45 1194

Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

SHANGHAI, June 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced dosing of...

2021-06-22 13:15 1380

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 15, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the ...

2021-06-15 09:06 1842

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 14, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the ...

2021-06-15 08:46 1330

Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab

SHANGHAI, May 6, 2021 /PRNewswire/ -- Asieris Pharmaceuticals ("Asieris") and BeiGene, Ltd. ("BeiGe...

2021-05-06 20:33 2113